MedTrace Logo

Rivaroxaban in Patients With Atrial Fibrillation Undergoing PCI

NCT03315650 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1632

Last updated 2022-03-31

No results posted yet for this study

Summary

This study evaluates the antithrombotic therapy in patients suffering from atrial fibrillation after stent implantation in Germany. Patients prescribed with the novel oral anticoagulant Rivaroxaban will be followed up over 14 months for their adherence to the medication schedule and for complications that occurred after index PCI.

Conditions

  • Non-valvular Atrial Fibrillation
  • Acute Coronary Syndrome
  • Percutaneous Coronary Intervention
  • Antithrombotic Therapy

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • IHF GmbH - Institut für Herzinfarktforschung

    lead OTHER

Principal Investigators

  • Uwe Zeymer, Prof. Dr. · Institut für Herzinfarktforschung (Institute for Cardiac Research)

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-03-31
Completion
2021-06-24

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03315650 on ClinicalTrials.gov